The current study is in line with the growing body of literature demonstrating that CHIP is a commonly occurring somatic mutation in patients with cancer exposed to cytotoxic therapies,25,26 given that all patients had received induction treatment prior to referral to HCT. This evidence concerns the gene STUB1 and cancer.